Objective To investigate the efficacy and safety of continuous renal replacement therapy(CRRT) in neonates with acute kidney injury(AKI). Method The AKI neonates treated with CRRT and admitted to our department from January 2015 to October 2021 were enrolled. Serum creatinine(Scr), blood urea nitrogen(BUN), urine output and the use of vasoactive drugs were analyzed at the three time points (before treatment, after 12-24 hours and at the end of the treatment). The complications and prognosis were also observed. Result A total of 12 neonates were involved, including 9 males and 3 females with gestational age of (36.6±3.0) weeks and birth weight of (2765.4±697.6)g. The primary diseases included birth asphyxia (7 cases), pneumonia (one case), congenital omphalocele (one case), congenital jejunal atresia (one case), neonatal septicemia (one case) and meconium aspiration syndrome (one case). Their median age was 3 (1, 4.8) days, and the operation time was (73.5±59.5) h. Finally, 4 patients survived, one patient was given up, and 7 patients died. There was no significant difference in age between cured neonates and those who died or were given up (Z=-0.352, P=0.725). The complications included electrolyte imbalance (8 cases), thrombocytopenia (5 cases) and tube blockage (3 cases). Compared with those before CRRT, BUN was significantly decreased 12～24h after CRRT (Z=-2.118, P=0.034), BUN showed a downward trend at the end of treatment, but the difference was not statistically significant (Z=-1.257, P=0.232); Scr levels were significantly decreased (t=4.528, P=0.001; t=3.372, P=0.006) and the urine output was significantly increased (Z=-2.670, P=0.008; Z=-2.937, P=0.003) after 12～24 hours of CRRT and at the end of CRRT. Eleven neonates were treated with vasoactive drugs before CRRT; after 12～24 hours of CRRT, one patient stopped using vasoactive drugs and 6 patients reduced the dosage; at the end of CRRT, 5 patients stopped using vasoactive drugs, and 3 patients reduced the dosage. Conclusion The application of CRRT in neonates with AKI is effective and safe, and the complications was controllable.
SUN Yi-Fan
,
CHU Xiao-Yun
,
WENG Bo-Wen
,
HONG Wen-Chao
,
GONG Xiao-Hui
,
CAI Cheng
. Evaluation of continuous renal replacement therapy in neonates with acute renal injury [J]. Chinese Journal of Blood Purification, 2022
, 21(08)
: 569
-572
.
DOI: 10.3969/j.issn.1671-4091.2022.08.006
[1] Spector B L, Misurac J M. Renal Replacement Therapy in Neonates[J]. Neoreviews, 2019,20(12):e697-e710.
[2] de Galasso L, Picca S, Guzzo I. Dialysis modalities for the management of pediatric acute kidney injury[J]. Pediatr Nephrol, 2020,35(5):753-765.
[3] Charlton JR, Boohaker L, Askenazi D, et al. Incidence and Risk Factors of Early Onset Neonatal AKI[J]. Clin J Am Soc Nephrol, 2019,14(2):184-195.
[4] Starr MC, Charlton JR, Guillet R, et al. Advances in Neonatal Acute Kidney Injury[J]. Pediatrics, 2021,148(5).
[5] Cleto-Yamane TL, Gomes CLR, Suassuna JHR, et al. Acute Kidney Injury Epidemiology in pediatrics [J]. J Bras Nefrol，2019，41(2)：275-283.
[6] 中华医学会儿科学分会新生儿学组. 连续性血液净化治疗新生儿急性肾损伤专家共识[J]. 中华儿科杂志，2021，59(04)：264-269.
[7] Selewski DT, Charlton JR, Jetton JG, et al. Neonatal Acute Kidney Injury[J]. Pediatrics, 2015,136(2):e463-e473.
[8] Jetton JG, Boohaker LJ, Sethi SK, et al. Incidence and outcomes of neonatal acute kidney injury (AWAKEN): a multicentre, multinational, observational cohort study[J]. Lancet Child Adolesc Health, 2017,1(3):184-194.
[9] Lee ST, Cho H. Fluid overload and outcomes in neonates receiving continuous renal replacement therapy[J]. Pediatr Nephrol, 2016,31(11):2145-2152.
[10] Ghobrial EE, Elhouchi SZ, Eltatawy SS, et al. Risk factors associated with acute kidney injury in newborns[J]. Saudi J Kidney Dis Transpl, 2018,29(1):81-87.
[11] 张婷，李晓文. 影响新生儿急性肾损伤预后的危险因素分析[J]. 临床儿科杂志，2021，39(09)：646-649.
[12] Tal L, Angelo JR, Akcan-Arikan A. Neonatal extracorporeal renal replacement therapy-a routine renal support modality?[J]. Pediatr Nephrol, 2016,31(11):2013-2015.
[13] Pedersen O, Jepsen SB, Toft P. Continuous renal replacement therapy for critically ill infants and children[J]. Dan Med J, 2012,59(2):A4385.
[14] Goldstein SL. Continuous renal replacement therapy: mechanism of clearance, fluid removal, indications and outcomes[J]. Curr Opin Pediatr, 2011,23(2):181-185.
[15] Erkol TG, Ekim M, Okulu E, et al. Continuous renal replacement therapy in critically ill children: single-center experience[J]. Turk J Med Sci, 2021,51(1):188-194.
[16] Cai C, Qiu G, Hong W, et al. Clinical effect and safety of continuous renal replacement therapy in the treatment of neonatal sepsis-related acute kidney injury[J]. BMC Nephrol, 2020,21(1):286.
[17] Symons JM, Chua AN, Somers MJ, et al. Demographic characteristics of pediatric continuous renal replacement therapy: a report of the prospective pediatric continuous renal replacement therapy registry[J]. Clin J Am Soc Nephrol, 2007,2(4):732-738.
[18] Zobel G, Ring E, Kuttnig M, et al. Five years experience with continuous extracorporeal renal support in paediatric intensive care[J]. Intensive Care Med, 1991,17(6):315-319.
[19] Symons JM, Brophy PD, Gregory MJ, et al. Continuous renal replacement therapy in children up to 10 kg[J]. Am J Kidney Dis, 2003,41(5):984-989.
[20] Buccione E, Guzzi F, Colosimo D, et al. Continuous Renal Replacement Therapy in Critically Ill Children in the Pediatric Intensive Care Unit: A Retrospective Analysis of Real-Life Prescriptions, Complications, and Outcomes[J]. Front Pediatr, 2021,9:696798.
